WO1996040041A3 - ANTICORPS DE L'ANTIGENE Fas CAPABLES D'INHIBER L'APOPTOSE - Google Patents

ANTICORPS DE L'ANTIGENE Fas CAPABLES D'INHIBER L'APOPTOSE Download PDF

Info

Publication number
WO1996040041A3
WO1996040041A3 PCT/US1996/009153 US9609153W WO9640041A3 WO 1996040041 A3 WO1996040041 A3 WO 1996040041A3 US 9609153 W US9609153 W US 9609153W WO 9640041 A3 WO9640041 A3 WO 9640041A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
fas antigen
inhibiting apoptosis
antigen capable
apoptosis
Prior art date
Application number
PCT/US1996/009153
Other languages
English (en)
Other versions
WO1996040041A2 (fr
Inventor
Thomas Gesner
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AU60914/96A priority Critical patent/AU6091496A/en
Publication of WO1996040041A2 publication Critical patent/WO1996040041A2/fr
Publication of WO1996040041A3 publication Critical patent/WO1996040041A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps capables de reconnaître et de fixer l'antigène Fas et d'autre part d'inhiber l'apoptose, ainsi que des hybridomes capables de produire ces anticorps. Sont également décrits des procédés pour l'utilisation de ces anticorps afin de traiter des maladies où l'apoptose est impliquée.
PCT/US1996/009153 1995-06-07 1996-06-05 ANTICORPS DE L'ANTIGENE Fas CAPABLES D'INHIBER L'APOPTOSE WO1996040041A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60914/96A AU6091496A (en) 1995-06-07 1996-06-05 Antibodies to fas antigen capable of inhibiting apoptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48346195A 1995-06-07 1995-06-07
US08/483,461 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040041A2 WO1996040041A2 (fr) 1996-12-19
WO1996040041A3 true WO1996040041A3 (fr) 1997-03-13

Family

ID=23920122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009153 WO1996040041A2 (fr) 1995-06-07 1996-06-05 ANTICORPS DE L'ANTIGENE Fas CAPABLES D'INHIBER L'APOPTOSE

Country Status (2)

Country Link
AU (1) AU6091496A (fr)
WO (1) WO1996040041A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU724579B2 (en) * 1996-04-01 2000-09-28 Sankyo Company Limited Anti-Fas recombinant antibodies and DNA therefor
ATE273713T1 (de) 1996-10-31 2004-09-15 Mochida Pharm Co Ltd Fas-antagonist für die prophylaxe oder therapie von gvhd
AU734758B2 (en) * 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
US20070129291A1 (en) * 2001-08-01 2007-06-07 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
KR20110128923A (ko) * 2009-03-12 2011-11-30 이메드 아베 인간 ｆａｓ에 대한 인간 항체 및 그의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010448A1 (fr) * 1990-01-19 1991-07-25 German Cancer Research Center Antigene de surface cellulaire associe a l'apoptose cellulaire
WO1995010540A1 (fr) * 1993-10-14 1995-04-20 Immunex Corporation Antagonistes de fas et leurs applications
DE4447484A1 (de) * 1994-04-08 1995-10-26 Deutsches Krebsforsch Hemmer von Apoptose

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010448A1 (fr) * 1990-01-19 1991-07-25 German Cancer Research Center Antigene de surface cellulaire associe a l'apoptose cellulaire
WO1995010540A1 (fr) * 1993-10-14 1995-04-20 Immunex Corporation Antagonistes de fas et leurs applications
DE4447484A1 (de) * 1994-04-08 1995-10-26 Deutsches Krebsforsch Hemmer von Apoptose

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. DHEIN ET AL.: "Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of Apo-1 cell surface antigens.", THE JOURNAL OF IMMUNOLOGY, vol. 149, no. 10, 15 November 1992 (1992-11-15), BALTIMORE, MD, USA, pages 3166 - 3173, XP002024490 *
M. ALDERSON ET AL.: "Regulation of apoptosis and T cell activation by Fas-specific mAb.", INTERNATIONAL IMMUNOLOGY, vol. 6, no. 11, November 1994 (1994-11-01), OXFORD, GB, pages 1799 - 1806, XP000616652 *
S. YONEHARA ET AL.: "Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes.", INTERNATIONAL IMMUNOLOGY, vol. 6, no. 12, December 1994 (1994-12-01), OXFORD, GB, pages 1849 - 1856, XP000616653 *
T. TAKIZAWA ET AL.: "Activation of the apoptotic Fas antigen-encoding gene upon influenza virus infection involving spontaneously produced beta-interferon.", VIROLOGY, vol. 209, no. 2, 1 June 1995 (1995-06-01), SAN DIEGO, CA, USA, pages 288 - 296, XP002024489 *

Also Published As

Publication number Publication date
AU6091496A (en) 1996-12-30
WO1996040041A2 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
WO2002030986A3 (fr) ANTICORPS HUMANISES ANTI-LT-β-R
DE69709632D1 (de) Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
WO1999062526A3 (fr) Traitement du myelome multiple au moyen d'anticorps du cd38 obtenus par genie genetique
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
EP0394946A3 (fr) Anticorps monoclonal humain et sa production et utilisation
WO2001014424A3 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
IL73883A (en) Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
WO2004001381A3 (fr) Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible
AU5674696A (en) Compounds that bind to p185 and methods of using the same
WO1996035774A3 (fr) Fragments d'angiostatine, angiostatine agregee et procedes d'utilisation
AU5686698A (en) Methods for the production of chicken monoclonal antibodies
AU7198291A (en) Human monoclonal antibodies against rabies viruses, the production and the use thereof
AU3657693A (en) Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and use therfor
EP0350690A3 (fr) Neutralisation des propriétés toxiques in vitro et in vivo du TNF-alfa par anticorps monoclonaux et fragments dérivés
WO1996040041A3 (fr) ANTICORPS DE L'ANTIGENE Fas CAPABLES D'INHIBER L'APOPTOSE
WO2002074251A3 (fr) Traitement par anticorps monoclonal du cancer du pancreas
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
WO2001037874A3 (fr) Traitement du psoriasis
CA2235845A1 (fr) Anticorps monoclonal specifique de la prostaglandine d synthetase
WO1991007986A8 (fr) Methode de traitement de choc septique
EP0874048A3 (fr) Protéin de hedgehog humaine
AU3923293A (en) Human monoclonal antibodies and methods for human monoclonal antibody production
WO1998051782A3 (fr) 3-hydroxyisobutyryl-coenzyme a hydrolase humaine
AU2001249546A1 (en) Methods for treating disease with antibodies to cxcr3
EP0369797A3 (fr) Anticorps monoclonal reconnaissant la protéine Reg

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX AM AZ BY KG KZ MD RU TJ TM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA